Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • FDC Rationality: Now 6...

    FDC Rationality: Now 6 months accelerated stability study data to be submitted, directs DCGI

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-03-27T16:48:55+05:30  |  Updated On 17 Aug 2021 11:34 AM IST

    New Delhi: Manufacturers of Fixed Dose Combinations drugs ( FDC drugs) which have declared rational and approved by Drugs Controller General India (DCGI) will now have to submit 6 months accelerated stability study data rather than 3 months accelerated data for their formulations. The Union Drug Controller recently wrote a letter to its state counterparts to this effect.


    The letter elaborated on the procedure to be followed by subsequent applicants in respect of Fixed Dose Combinations (FDCs) declared as rational by Prof. Kokate Committee and approved by Drugs Controller General(India) DCG(I).

    The letter directed all the states and Union Territories drug controllers to ask the concerned manufacturers/stakeholders to follow the procedure as laid down by the Directorate for obtaining the product license w.r.t. FDCs declared as rational by Prof. Kokate Committee and approved by Drugs Controller General(India) DCG(I).


    Also Read: New law for labelling Drugs, Fixed-Dose Combinations: Govt issues Gazette

    The letter clearly stated that earlier 3 months accelerated Stability studies data was required to be submitted by the applicants for obtaining the product license from drug controller's office.


    "However, the matter was discussed in the 55th DCC meeting held on 31-01-2019 & 01.02.2019 and it was decided that applicant should submit 6 months accelerated stability study data in place of 3 months accelerated data so that there is no disparity," the letter added


    Accelerated Stability studies are the studies designed to increase the rate of chemical degradation and physical change of a drug by using exaggerated storage conditions as part of the formal stability testing programme. The main aim of accelerated stability study is to predict the stability profile of a drug product that prediction of shelf life of the product before launching into market.


    The notification further clarified that the manufacturers who are not holding product licence prior to 01.10.2012 should generate and submit stability study data after obtaining From-29 from the concerned state licensing authority (SLA).


    Also Read: No relief for Fixed Dose Combinations in Type 2 Diabetes: HC rejects pharma plea
    55th DCC meetingCDSCOCentral Drugs Standard Control OrganizationDCGIdrugsFDCFDC drugsFDCsfixed dose combinationsform 29medicinesPharma Policy newspolicy newsproduct licenseSLAstability studyState Licensing Authorityunion territories

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok